Racial and Ethnic Inequities in Diabetes Pharmacotherapy: Black and Hispanic Patients Are Less Likely to Receive SGLT2is and GLP1as
J Gen Intern Med
.
2022 Oct;37(13):3501-3503.
doi: 10.1007/s11606-022-07428-1.
Epub 2022 Feb 9.
Authors
Christopher Cai
1
,
Steffie Woolhandler
2
3
,
Danny McCormick
3
,
David U Himmelstein
2
3
,
Jessica Himmelstein
3
,
Elizabeth Schrier
4
,
Samuel L Dickman
5
6
Affiliations
1
Department of Medicine, Internal Medicine Residency at Brigham and Women's Hospital/Harvard Medical School, Boston, MA, USA. ccai@bwh.harvard.edu.
2
City University of New York at Hunter College, New York City, NY, USA.
3
Cambridge Health Alliance/Harvard Medical School, Cambridge, MA, USA.
4
University of California San Francisco (UCSF) School of Medicine, San Francisco, CA, USA.
5
Planned Parenthood South Texas, San Antonio, TX, USA.
6
The University of Texas at Austin, Austin, TX, USA.
PMID:
35141853
PMCID:
PMC9551144
DOI:
10.1007/s11606-022-07428-1
No abstract available
MeSH terms
Black People
Black or African American
Diabetes Mellitus* / drug therapy
Diabetes Mellitus* / epidemiology
Ethnicity
Hispanic or Latino*
Humans
Racial Groups
United States